Prediction and analysis of the global top 10 cancer drug sales pattern in 2020

Market demand: according to the World Health Organization, about 8.2 million people die of cancer every year, accounting for about 13% of the global death toll Who predicts a 70% increase in new cancer cases over the next two decades Cancer is a cruel disease, patients are willing to spend a very high cost to treat the disease In business, cancer drugs are the strongest guarantee of high income, and many pharmaceutical and biotechnology companies are focusing on this demand According to statistics 2016 annual report, IMS, and relevant information of public annual report, Xiaobian old beggar of Tianqiao analyzed the sales pattern of top ten cancer drugs in the world in 2020 1 The total sales volume of top 10 cancer drugs in 2016 is 43097 (million US dollars), and the total sales volume in 2020 is expected to be 59888 (million US dollars), with an increase rate of 38.96% It is estimated that the first drug to break the $10000 million barrier is Revlimid (celgene) The top 10 drugs in the global drug sales list in 2016 are: rituxan (5), Revlimid (6), Avastin (7), Herceptin (8) It can be seen that tumor drugs occupy an important position in the whole drug ranking Competitive analysis: according to the relevance of the indications of the drugs, the drugs with competitive relations are: revimid and imbruvica, Avastin and opdivo and keytruda, ibrance and perjeta and Herceptin All three will be more competitive Less competitive: rituxan, xtandi Among the top 10 drugs whose sales will decrease compared with 2016 in 2020 are Avastin, rituxan and Herceptin Reasons for analysis: Avastin's other manufacturers, including Samsung bioepis, Bolin eel, Pfizer, aryogen Biopharmaceutics, reliance life sciences and Fujifilm Kyowa Kirin biology, all have Avastin biological products in phase 3 Rituxan (Roche) will face its bio generic products in Europe and the United States by the end of 2017 There are already several cloned drugs in emerging markets in India, Russia and Latin America Celltrion is a leader in the development of rituxan biosimilars, and the European Drug Administration (EMA) submitted the ct-p10 version of Roche in late 2015 Another candidate from Novartis pharmaceutical company Sandoz was submitted in the European Union in May, while the Polish company mabionsa said it would submit the version by the end of the year Herceptin's position at the top of the HER2 tree is threatened by biosimilars as the drug's main EU patent expires in 2014 and expires in the US in 2019 Mylan and biocon have launched a biosimilars, cannab, in India, while celltrion's biosimilars in the Korean market are herzuma At the same time, mylan and biocon are also launched in the EU, and Samsung bioepis has submitted the application of its Sb3 candidate and obtained approval 2 According to the analysis of the overall trend of TOP10 cancer drugs, the top three enterprises are: Roche, celgene, abbvie / J & J, especially Roche of Top1, accounting for 49.73% (2016) of the sales of TOP10, accounting for half of the total It is expected that by 2020, it will drop to 35.70% 3 Analysis of TOP10 tumor drug details: TOP10 / 10 drug name: keytruda Chinese Name: Bevacizumab general name: pembrolizumab enterprise: Merck indications: advanced melanoma; non-small cell lung cancer; head and neck squamous cell carcinoma brief introduction: Merck's immunotherapy is shown in patients with unresectable or metastatic melanoma and metastatic non-small cell lung cancer Growth rate in 2016: 147.70% ranking of global drug sales in 2016: 82 estimated sales in 2020: US $3560 million sales trend analysis over the years (unit: US $million): Top9 / 10 drug name: Herceptin Chinese Name: trastuzumab generic name: trastuzumab enterprise: Roche indication: ER2 positive breast cancer Introduction: Herceptin is used to treat early breast cancer with positive human epidermal growth factor receptor 2 (HER2 +), and has spread to lymph nodes, or HER2 is positive and has not yet spread to lymph nodes It is also used for metastatic breast cancer and gastric cancer The patent expires in the United States in 2019 Growth rate in 2016: 3.72% ranking of global drug sales in 2016: 8 estimated sales in 2020: US $4573 million trend analysis of sales over the years (unit: US $million): Top 8 / 10 drug name: perjeta Chinese Name: patuzumab common name: pertuzumab enterprise: Roche indication: HER2 + metastatic breast cancer patients who have not received anti-HER2 treatment or chemotherapy before Introduction: perjeta is used for metastatic breast cancer It can also be used for HER2 positive, locally advanced, inflammatory or early breast cancer Growth rate in 2016: 27.75% ranking of global drug sales in 2016: 55 estimated sales in 2020: US $4669 million trend analysis of sales over the years (unit: US $million): Top 7 / 10 drug name: ibrance Chinese Name: pabosini common name: palbociclib enterprise: Pfizer indication: metastatic breast cancer Brief introduction: ibrance is used to treat hormone receptor positive (HR +, HER2 -) breast cancer that has spread to other parts of the body (metastatic) Growth rate in 2016: 195.30% global drug sales ranking in 2016: 48 estimated sales in 2020: US $4722 million sales trend analysis over the years (unit: US $million): Top 6 / 10 Drug name: rituxan Chinese Name: Rituximab general name: Rituximab enterprise: Roche indication: non Hodgkin lymphoma; chronic lymphocytic leukemia Introduction: rituxan is suitable for non Hodgkin's lymphoma, chronic lymphoblastic leukemia, rheumatoid arthritis, multiple vasculitis (GPA), granulomatosis, Wegener's granulomatosis and microscopic vasculitis (MPA) Last year, it was one of the top ten drugs in the world, with global sales of US $7.5 billion, but its patent expired in 2018 Growth rate in 2016: 3.26% ranking of global drug sales in 2016: 5 estimated sales in 2020: US $5407 million trend analysis of sales over the years (unit: US $million): Top 5 / 10 drug name: xtandi Chinese Name: enzalutamide common name: enzalutamide enterprise: Mediation & astralas indications: prostate cancer Introduction: xtandi is an androgen receptor inhibitor used to treat patients with metastatic castration resistant prostate cancer Growth rate in 2016: 88.59% ranking of global drug sales in 2016: no estimated sales volume in 2020: analysis of sales trend of US $5700 million over the years (unit: US $million): Top 4 / 10 drug name: opdivo Chinese Name: nevumab generic name: nivolumab enterprise: BMS indications: non-small cell lung cancer; metastatic melanoma renal cell carcinoma; classic Hodgkin lymphoma Introduction: opdivo is a programmed death receptor-1 (PD-1) blocking antibody, which is used to treat patients with unresectable or metastatic melanoma, metastatic non-small cell lung cancer and advanced renal cell carcinoma Growth rate in 2016: 300.64% ranking of global drug sales in 2016: 20 estimated sales in 2020: US $6201 million sales trend analysis over the years (unit: US $million): Top 3 / 10 drug name: Avastin Chinese Name: Bevacizumab generic name: Bevacizumab enterprise: Roche Indications: colorectal cancer; non-small cell lung cancer; ovarian cancer; cervical cancer; renal cell carcinoma; glioblastoma Introduction: Avastin is a vascular endothelial growth factor specific angiogenesis inhibitor, which is used to treat metastatic colorectal cancer, non squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, platinum resistant recurrent epithelial ovarian and fallopian tube or primary peritoneal cancer Growth rate in 2016: 1.46% ranking of global drug sales in 2016: 7 estimated sales volume in 2020: US $6733 million trend analysis of sales volume over the years (unit: US $million): top 2 / 10 drug name: imbruvica Chinese Name: irutinib general name: ibrutinib enterprise: abbvie / J & J Indications: chronic lymphocytic leukemia; mantle cell lymphoma; Waldenstr ö m macroglobulinemia brief introduction: imbruvica is suitable for chronic lymphocytic leukemia (CLL), with 17p deletion of chronic lymphocytic leukemia (CLL), Waldenstr ö m macroglobulinemia (WM) and mantle cell lymphoma (MCL), which has received at least one previous treatment Growth rate in 2016: 113.65% ranking of global drug sales in 2016: 28 estimated sales in 2020: 8213 million US dollars sales trend analysis over the years (unit: million US dollars): Top 1 / 10 drug name: revimid Chinese Name: lenalidomide company: celgene indications: multiple myeloma; Myelodysplastic Syndrome nested cell lymphoma Introduction: Revlimid is used to treat multiple myeloma and mantle cell lymphoma It is also used for the growth rate of myelodysplastic syndrome patients related to 5q cytogenetic abnormality in 2016: 20.22% global drug sales ranking 2016: 6 estimated sales in 2020: 10110 million US dollars sales trend analysis over the years (unit: million US dollars): Note: This article is original by the author of yaozhi.com, welcome to reprint, please indicate the source and author when reprint, thank you!